STERIS plc STE
Healthcare · Medical Devices · United States · S&P 500
Based on the available data, STERIS plc gets an algorithmic score of 56/100. It trades at 210.65 $, with a bearish technical trend (RSI 39.3) and 25.3% annual volatility.
Updated: 2026-09-30
Open in the interactive tool →
Strengths
- Low-debt balance sheet.
- Low beta (0.55): defensive profile.
Weaknesses
- —
Fundamentals
| P/E | 25.78 |
| Forward P/E | 17.20 |
| PEG | 1.74 |
| P/B | 2.85 |
| EV/EBITDA | 13.48 |
| P/S | 3.40 |
| ROE % | 11.39 |
| ROA % | 6.80 |
| Gross margin % | 44.42 |
| Operating margin % | 19.15 |
| Net margin % | 13.33 |
| Revenue growth % (y/y) | 7.30 |
| Earnings growth % (y/y) | 14.00 |
| Revenue CAGR % | 9.38 |
| Earnings CAGR % | 94.07 |
| Debt/Equity % | 28.31 |
| Current ratio | 1.91 |
| FCF yield % | 4.73 |
| Dividend yield % | 1.22 |
| Payout % | 30.81 |
Returns
| 1 month | -9.6 % |
| 3 months | +0.3 % |
| 6 months | -3.4 % |
| YTD | -15.0 % |
| 1 year | -14.7 % |
| 3 years | -3.2 % |
| 5 years | +4.0 % |
Risk
| 1-year volatility | 25.3 % |
| Beta | 0.55 |
| 5-year max drawdown | -36.2 % |
| Sharpe 1A | -0.66 |
Macroeconomic context
Defensive with structural growth (ageing population). Risks: drug-pricing regulation, patents and clinical trials. Low correlation with the cycle. As a US company, its valuation depends on the Fed, 10-year Treasury yields and the US earnings cycle.
How the score is calculated
The score combines profitability (ROE, ROA, net margin), growth (revenue and earnings), valuation (P/E, EV/EBITDA, free cash flow), financial strength (debt and liquidity; not applied to banks and insurers) and momentum (6 and 12-month returns and trend). It is an educational quantitative filter, not a buy or sell recommendation.